The most widespread biomarkers approved by the USA Food and Drug Administration (FDA) and European Medicine Agency (EMA) [4] for urology and prostate cancer (PCa) disease include prostate-specific antigen (PSA) [5], carbohydrate antigen 125 (CA 125) [3], and carcinoembryonic antigen (CEA) [6], among others [7]. Here, KLK3 is linked to posterior cortical atrophy.